The latest biotech news

News and Trends 9 Aug 2022

Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, has initiated a phase 1b multiple ascending dose study of UPB-101 in asthma patients with the dosing of the first patient. Meanwhile, a possible way to tackle one of the underlying causes of asthma has been developed by researchers from Aston University and […]

August 9, 2022 - 5 minutesmins - By Jim Cornall

Approval for Small Pharma major depressive disorder clinical trials

News and Trends 9 Aug 2022

Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment

Relmada Therapeutics, Inc., a late-stage biotech company addressing diseases of the central nervous system (CNS), has been given U.S. Food and Drug Administration (FDA) Fast Track designation to REL-1017, the company’s novel NMDA receptor (NMDAR) channel blocker, as a monotherapy for the treatment of major depressive disorder (MDD). “The receipt of Fast Track Designation represents […]

August 9, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 9 Aug 2022

Start-up receives science and business support at Lab Hotel

Stevenage Bioscience Catalyst (SBC) has welcomed Inspira Pharmaceuticals to its Lab Hotel, a facility offering free lab and office accommodation for six months to start-ups. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop. Biotech start-up Rory McGoldrick, co-founder and CEO of […]

August 9, 2022 - 2 minutesmins - By Liza Laws

News and Trends 9 Aug 2022

Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment

A global collaboration was announced today (August 9) between Mersana Therapeutics Inc and GSK plc that will give GSK the option to co-develop and commercialize an antibody drug conjugate (ADC). The ADC called XMT-2056 is designed to activate the innate immune system through STING signaling in both tumor-resident immune cells and in tumor cells. Anna […]

August 9, 2022 - 3 minutesmins - By Liza Laws

CRISPR Therapeutics, CRISPR-Cas9, genome editing, biotech

News and Trends 9 Aug 2022

Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability

CRISPR/Cas9 is a commonly used gene editing technique. CRISPR allows the introduction of a desired DNA sequence into (virtually) any spot of the genome, thus modifying or inactivating a gene. The technique is widely used in biomedical research and some CRISPR-based therapies are in clinical trials for the treatment of human blood disorders, some types […]

August 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 9 Aug 2022

Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents

Formulations of a drug that can help a number of inflammatory diseases including rheumatoid arthritis and Crohn’s disease have been issued patents by the European Patent Office (EPO). The EPO issued two patents that will protect Arecor Therapeutics’ formulations of high-concentration adalimumab until 2038. The company made the announcement today (August 9). Monoclonal antibody Adalimumab, […]

August 9, 2022 - 3 minutesmins - By Liza Laws

News and Trends 9 Aug 2022

Pfizer and Valneva to start phase 3 Lyme disease vaccine study

Pfizer Inc. and Valneva SE have initiated a phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR), to investigate the efficacy, safety and immunogenicity of their investigational Lyme disease vaccine candidate, VLA15. “With increasing global rates of Lyme disease, providing a new option for people to help protect themselves from the disease is […]

August 9, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Positive topline results from a phase 3 trial looking at the effect of a drug to treat schizophrenia were announced today (August 8). Karuna Therapeutics Inc, the founded entity of PureTech Health plc, said results from the EMERGENT-2 trial evaluating the efficacy, safety and tolerability of KarXT (xanomeline-trospium) in adults met its primary endpoint and […]

August 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca

A medication used to treat non-small cell lung carcinomas (NSCLC) with specific mutations has demonstrated a 49% objective response rate (ORR) in patients. AstraZeneca and HUTCHMED announced that TAGRISSO Plus Savolitinib – a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor – was helping patients with high levels of mesenchymal epithelial transition (MET). […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

Dallas College has been awarded a U.S. Economic Development Administration grant to help underserved communities access living-wage jobs in biotechnology. The college noted biotech is a sector poised to grow exponentially with the need for additional highly skilled employees in North Texas, according to the latest labor market intelligence. With approximately $8.8 million in funds […]

August 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 8 Aug 2022

HUTCHMED drug in colorectal cancer trial meets primary endpoint

A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint of overall survival (OS) in patients with the disease. China’s HUTCHMED Limited announced today (August 8) that the phase 3 FRESCO-2 trial investigating the use of fruquintinib had met all secondary endpoints too. The […]

August 8, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Aug 2022

Epigenic Therapeutics raises $20M for gene editing technology

Epigenic Therapeutics Co., Ltd., a Chinese biotech gene editing company, has secured $20 million in Series Angel and Pre-A funding. The Series Pre-A funding came from investments by Morningside Venture Capital, Kingray Capital, Trinity Innovation Fund and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. The proceeds will be used to advance the company’s […]

August 8, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Asthma in the spotlight as Upstream Bio starts trial and UK universities propose new long-term treatment

Relmada Therapeutics gets Fast Track designation for major depressive disorder treatment

Start-up receives science and business support at Lab Hotel

Mersana Therapeutics announces collaboration with GSK for the co-development of cancer treatment

Study says gene editing with CRISPR/Cas9 can lead to cell toxicity and genome instability

Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents

Pfizer and Valneva to start phase 3 Lyme disease vaccine study

Positive trial results for schizophrenia drug, KarTX, from PureTech’s founded entity, Karuna Therapeutics

Lung cancer trial patients responding well to combination treatment offered by HUTCHMED and AstraZeneca

Dallas College gets $8.8M grant to grow biotech workforce in North Texas

HUTCHMED drug in colorectal cancer trial meets primary endpoint

Epigenic Therapeutics raises $20M for gene editing technology

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!